Zika Virus Vaccines Shot to Be Available to Public by 2018, Forecasts DPI Research in Its New Report Available at MarketPublishers.com

17 Jan 2017 • by Natalie Aster

LONDON – Pregnant women expose themselves to the highest risk on account of the relation the virus has to severe inborn defects. Women that are infected with the Zika virus across pregnancy are most likely to have a baby with microcephaly. Complications of this disease comprise seizures and developmental problems.

Owing to the grave nature of the global risk, the microcephaly cases pertaining to the Zika virus have been declared by the WHO a global emergency. With no existing vaccines or cure the virus along with its risks is set to keep on spreading. The WHO forecasts around 4 million Zika cases in North America and South America by 2016-end and the World Bank projects the economic influence for 2016 in the Caribbean and Latin America to be estimated at around USD 3.5 billion.

In fear of Zika virus reaching unparalleled heights, vaccines to prevent getting Zika virus are growing in popularity. Many government authorities and research organisations support pharmacos for the development and production of Zika virus vaccines. A shot of Zika virus vaccines is projected to publically available by 2018.

NewLink Genetics, ImmunoVaccines Inc, Valneva, Sanofi Pasteur, Inovio Pharmaceuticals, Inc, and Bharat Biotech International Pvt. Ltd. are some of the most prominent players operating in the marketplace.    

New research report “Zika Virus Vaccines by Company Profile, Deals Type, Funding, Clinical Trials Insight, Regulatory Landscape & Recent Development” elaborated by by DPI Research provides an all-round, detailed assessment of the Zika virus vaccines. It gives a comprehensive overview of Zika virus covering signs and symptoms, diagnosis, transmission, therapy and prevention methods. The study describes the actual state and areas with Zika virus, casts light on the funding in the research of Zika virus vaccines. The report offers an assessment of clinical research and regulatory scenario of the development of Zika virus vaccines. Furthermore, the report canvasses the competitive scene of the market and offers exhaustive profiles of the top players engaged in the Zika virus vaccines development.

More new reports by the publisher can be found at DPI Research & Marketing Solutions page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com